top of page
Public Statements
Every statement CANN has issued — press releases, public comments filed with federal and state agencies, and fact sheets — collected in one searchable archive. Use the filters to browse by year, topic, or document type.
Public comments and testimony are part of how CANN does policy work in public. We file them, archive them, and make them accessible because the record matters.
On The Record
Our ten most recent public comments and press releases. Search the full document archive below for everything else.
Public Comments
Document Title | Document Summary | Publication Date |
|---|---|---|
CANN Written Comment: Maryland PDAB Cost Review Study Process Revisions (June 2026) | Comment to the Maryland PDAB on proposed amendments to COMAR 14.01.04 Cost Review Study Process, addressing the MCDB ERISA data blind spot, MDPN/IRA inclusion criteria, the risk that foreign data introduces QALY-based methods prohibited by the ADA, and the need for greater patient-centered focus. | 06/01/2026 |
CANN Written Comment: Maryland PDAB Ongoing Board Developments (May 2026) | Written comment to the Maryland PDAB on patient outreach concerns, the Board's mixed Farxiga (no UPL) and Jardiance (proposed UPL) decisions, and the moral and ethical concerns of testing UPL implementation on state mental health facilities and university health plans. | 05/12/2026 |
CANN Public Comment: Colorado PDAB Ongoing Board Activity (May 2026) | CANN raises questions about Colorado's PDAB ongoing board activity, focusing on HB23-1225 drug eligibility thresholds, the effectiveness of upper payment limits for patient out-of-pocket affordability, formulary protection gaps, and patient engagement via the PDAAC toolkit and Community Partner Network. | 05/11/2026 |
CANN Statement on Maryland PDAB's 'Plan of Action' (April 2026) | Public statement from Jen Laws, President & CEO of CANN, responding to the Maryland PDAB's mixed Jardiance and Farxiga decisions, and urging state leadership to require demonstrated patient access protections before policies are finalized. | 04/22/2026 |
CANN Public Comment: Oregon PDAB March 2026 | Comment addressing Oregon PDAB's March 2026 meeting on orphan drug interpretation and support for rebate pass-through affordability solutions. | 03/01/2026 |
CANN Written Comment: Maryland PDAB March 2026 | Written comment addressing Maryland PDAB's March 2026 meeting on implementation concerns missing baseline data and need for non-UPL affordability solutions. | 03/01/2026 |
CANN Public Comment: Washington SB 5981 — 340B (Ways and Means) | Comment opposing SB 5981 on 340B expansion citing Medicaid sustainability and program integrity concerns at fiscal committee stage. | 02/05/2026 |
CANN Public Comment: Washington HB 2145 — 340B Program | Comment opposing HB 2145 expanding 340B contract pharmacies without oversight safeguards or patient-focused accountability measures. | 02/04/2026 |
CANN Public Comment: Virginia SB 278 — 340B (Finance) | Comment opposing SB 278 citing interference with federal 340B structure and Medicaid sustainability concerns. | 02/04/2026 |
CANN Public Comment: Missouri SB 1213/SB 1178 — 340B Transparency | Comment supporting SB 1213/SB 1178 requiring 340B program transparency and accountability reporting from hospitals and covered entities. | 02/03/2026 |
Press Releases
Document Title | Document Summary | Publication Date |
|---|---|---|
CANN Statement on Maryland PDAB's 'Plan of Action' (April 2026) | Public statement from Jen Laws, President & CEO of CANN, responding to the Maryland PDAB's mixed Jardiance and Farxiga decisions, and urging state leadership to require demonstrated patient access protections before policies are finalized. | 04/22/2026 |
CANN CEO Response to Industry Critiques of 340B Analysis | CANN CEO's response defending patient advocacy analysis of 340B program abuses against industry consultant critiques, asserting CANN speaks from lived patient experience while critics profit from the program. | 02/11/2026 |
CANN Releases Policy Brief on State 340B Conflicts with Federal Reforms | Press release announcing CANN's policy brief detailing conflicts between state 340B mandate laws and proposed federal reform legislation including the ACCESS Act and SUSTAIN draft. | 02/03/2026 |
CANN Statement to Senate HELP Committee on 340B Reform | Statement urging the Senate HELP Committee to prioritize patient-centered 340B reforms, highlighting PBM profiteering concerns and criticizing the absence of patient representation on witness panels. | 10/21/2025 |
CANN Statement on California SB 144: ADAP Rebate Fund Diversion | Statement opposing California SB 144 proposing $20 million diversion from ADAP rebate fund, asserting this violates Ryan White statutory requirements protecting HIV-specific program dollars. | 09/17/2025 |
CANN Statement Supporting 340B ACCESS Act (HR 5256) | Statement supporting the bipartisan 340B ACCESS Act seeking to restore patient focus through transparency requirements, PBM accountability measures, and administrator fee limits. | 09/11/2025 |
CANN Statement on CBO Report Confirming 340B Program Abuse | Statement responding to CBO report confirming 340B program abuse, noting FQHCs comprise only 13% of program purchases versus 87% for large hospitals, underscoring the need for patient-focused reform. | 09/10/2025 |
Joint Statement on Proposed Cuts to HIV Prevention Programs | Joint statement from ADAP Advocacy Association and CANN expressing concern about reported HHS cuts to CDC HIV prevention programs including PrEP initiatives that could impact 36% of nationwide coverage. | 03/19/2025 |
CANN Announces 2024 HIV Advocacy Scholarship Honorees | CANN announces three 2024 HIV advocacy scholarship winners recognized for leadership in HIV/AIDS public policy and access to care under Medicaid and Ryan White programs. | 05/22/2024 |
CANN Launches '340B: What About Me?' Campaign | CANN launches the '340B: What About Me?' campaign highlighting abuses within the 340B program and calling for congressional oversight of the multi-billion-dollar federal drug discount program. | 01/29/2024 |
Document Library
Document Title | Document Summary | Publication Date | Content Type |
|---|---|---|---|
CANN Written Comment: Maryland PDAB Cost Review Study Process Revisions (June 2026) | Comment to the Maryland PDAB on proposed amendments to COMAR 14.01.04 Cost Review Study Process, addressing the MCDB ERISA data blind spot, MDPN/IRA inclusion criteria, the risk that foreign data introduces QALY-based methods prohibited by the ADA, and the need for greater patient-centered focus. | 06/01/2026 | Public Comment |
CANN Written Comment: Maryland PDAB Ongoing Board Developments (May 2026) | Written comment to the Maryland PDAB on patient outreach concerns, the Board's mixed Farxiga (no UPL) and Jardiance (proposed UPL) decisions, and the moral and ethical concerns of testing UPL implementation on state mental health facilities and university health plans. | 05/12/2026 | Public Comment |
CANN Public Comment: Colorado PDAB Ongoing Board Activity (May 2026) | CANN raises questions about Colorado's PDAB ongoing board activity, focusing on HB23-1225 drug eligibility thresholds, the effectiveness of upper payment limits for patient out-of-pocket affordability, formulary protection gaps, and patient engagement via the PDAAC toolkit and Community Partner Network. | 05/11/2026 | Public Comment |
CANN Statement on Maryland PDAB's 'Plan of Action' (April 2026) | Public statement from Jen Laws, President & CEO of CANN, responding to the Maryland PDAB's mixed Jardiance and Farxiga decisions, and urging state leadership to require demonstrated patient access protections before policies are finalized. | 04/22/2026 | Public Comment,Press Release |
CANN Public Comment: Oregon PDAB March 2026 | Comment addressing Oregon PDAB's March 2026 meeting on orphan drug interpretation and support for rebate pass-through affordability solutions. | 03/01/2026 | Public Comment |
CANN Written Comment: Maryland PDAB March 2026 | Written comment addressing Maryland PDAB's March 2026 meeting on implementation concerns missing baseline data and need for non-UPL affordability solutions. | 03/01/2026 | Public Comment |
CANN CEO Response to Industry Critiques of 340B Analysis | CANN CEO's response defending patient advocacy analysis of 340B program abuses against industry consultant critiques, asserting CANN speaks from lived patient experience while critics profit from the program. | 02/11/2026 | Press Release |
CANN Public Comment: Washington SB 5981 — 340B (Ways and Means) | Comment opposing SB 5981 on 340B expansion citing Medicaid sustainability and program integrity concerns at fiscal committee stage. | 02/05/2026 | Public Comment |
CANN Public Comment: Washington HB 2145 — 340B Program | Comment opposing HB 2145 expanding 340B contract pharmacies without oversight safeguards or patient-focused accountability measures. | 02/04/2026 | Public Comment |
CANN Public Comment: Virginia SB 278 — 340B (Finance) | Comment opposing SB 278 citing interference with federal 340B structure and Medicaid sustainability concerns. | 02/04/2026 | Public Comment |
CANN Releases Policy Brief on State 340B Conflicts with Federal Reforms | Press release announcing CANN's policy brief detailing conflicts between state 340B mandate laws and proposed federal reform legislation including the ACCESS Act and SUSTAIN draft. | 02/03/2026 | Press Release |
CANN Public Comment: Missouri SB 1213/SB 1178 — 340B Transparency | Comment supporting SB 1213/SB 1178 requiring 340B program transparency and accountability reporting from hospitals and covered entities. | 02/03/2026 | Public Comment |
CANN Written Comment: Maryland PDAB Informational Hearing February 2026 | Testimony on Maryland PDAB's flawed cost review study process and incomplete policy review methodology at February 2026 informational hearing. | 02/01/2026 | Public Comment |
CANN Public Comment: Virginia SB 278 — 340B (Education and Health) | Comment opposing SB 278 on federal-state conflicts and unclear regulatory burden impacts on the 340B program. | 01/28/2026 | Public Comment |
CANN Public Comment: Michigan HB 4878 — 340B Program (January 2026) | Comment opposing HB 4878 on 340B program requirements citing Medicaid sustainability threats and federal-state policy conflicts. | 01/28/2026 | Public Comment |
CANN Public Comment: Virginia SB 278 — 340B (Senate Commerce and Labor) | Comment opposing SB 278 conditioning drug manufacturer registration on 340B distribution assurances without addressing patient access. | 01/27/2026 | Public Comment |
CANN Public Comment: Washington SB 5981 — 340B (Health Committee) | Comment opposing SB 5981 expanding 340B contract pharmacies without transparency requirements or patient access protections. | 01/13/2026 | Public Comment |
Policy Brief: Conflicts Between State 340B Laws and Proposed Federal Reforms | Policy brief analyzing conflicts between 19 state 340B expansion laws and proposed federal reform legislation, documenting that state contract pharmacy mandates have not improved patient access or affordability. | 01/01/2026 | Policy Brief |
340B Ensure Support of Vulnerable Patients Act — Washington Handout (2026 Update) | State-specific advocacy handout for Washington calling for patient-centered 340B reforms requiring transparency in how hospitals and covered entities direct 340B drug discount savings to benefit vulnerable patients. | 01/01/2026 | Educational Resource |
Policy Brief: State 340B Mandates Do Not Improve Patient Access | Evidence-based analysis demonstrating that state contract pharmacy mandate laws fail to improve patient affordability or reduce medication abandonment rates, with data from multiple state implementations. | 01/01/2026 | Policy Brief |
Showing 1–20 of 483 documents
bottom of page